Paolo Abada

3.8k total citations · 3 hit papers
63 papers, 2.3k citations indexed

About

Paolo Abada is a scholar working on Hepatology, Oncology and Cancer Research. According to data from OpenAlex, Paolo Abada has authored 63 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hepatology, 27 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Paolo Abada's work include Hepatocellular Carcinoma Treatment and Prognosis (33 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Paolo Abada is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (33 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Paolo Abada collaborates with scholars based in United States, Japan and Germany. Paolo Abada's co-authors include Masatoshi Kudo, Andrew X. Zhu, Richard S. Finn, Weijing Sun, Richard D. Kim, Michael A. Morse, Aiwu Ruth He, Stephen B. Howell, Josep M. Llovet and Peter R. Galle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Paolo Abada

60 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →
The Role of Angiogenesis in Hepatocellular Carcinoma

2018 417 citations Paolo Abada, Richard S. Finn et al. Clinical Cancer Research profile →
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

2019 409 citations Peter R. Galle, Masatoshi Kudo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paolo Abada United States	19	1.2k	652	602	538	508	63	2.3k
Chia-Jui Yen Taiwan	28	777 0.7×	955 1.5×	1.1k 1.8×	613 1.1×	420 0.8×	63	2.7k
Philippa Newell United States	11	1.2k 1.1×	902 1.4×	1.5k 2.5×	916 1.7×	600 1.2×	16	3.3k
Renumathy Dhanasekaran United States	28	915 0.8×	677 1.0×	1.0k 1.7×	549 1.0×	538 1.1×	85	2.6k
Thomas Decaens France	31	2.3k 1.9×	720 1.1×	1.1k 1.9×	591 1.1×	1.3k 2.5×	141	3.9k
Chunyi Hao China	24	403 0.3×	871 1.3×	724 1.2×	330 0.6×	248 0.5×	135	2.1k
Luca Faloppi Italy	25	457 0.4×	807 1.2×	580 1.0×	601 1.1×	220 0.4×	92	1.8k
Robert Montal Spain	11	921 0.8×	614 0.9×	817 1.4×	682 1.3×	398 0.8×	19	2.2k
Atsushi Kudo Japan	28	639 0.5×	1.0k 1.6×	725 1.2×	474 0.9×	653 1.3×	129	2.4k
Bazarragchaa Damdinsuren Japan	28	563 0.5×	802 1.2×	858 1.4×	485 0.9×	196 0.4×	42	2.3k
Makoto Chuma Japan	21	806 0.7×	323 0.5×	643 1.1×	251 0.5×	669 1.3×	70	1.9k

Countries citing papers authored by Paolo Abada

Since Specialization

Citations

This map shows the geographic impact of Paolo Abada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Abada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Abada more than expected).

Fields of papers citing papers by Paolo Abada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Abada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Abada. The network helps show where Paolo Abada may publish in the future.

Co-authorship network of co-authors of Paolo Abada

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Abada. A scholar is included among the top collaborators of Paolo Abada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Abada. Paolo Abada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jain, Nitin, Toby A. Eyre, Katherine B. Winfree, et al.. (2025). Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 66(8). 1400–1412. 2 indexed citations

Markowitz, Jessica T., et al.. (2024). Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. Journal of Patient-Reported Outcomes. 8(1). 8–8. 2 indexed citations

Ni, Lan, Azhar Khan, Amanda Long, et al.. (2023). Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm. Clinical Pharmacology & Therapeutics. 114(1). 77–87. 3 indexed citations

Ogata, Takatsugu, Yukiya Narita, Zev A. Wainberg, et al.. (2023). Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study. Journal of the Korean Gastric Cancer Association. 23(2). 289–289. 1 indexed citations

Jain, Nitin, Toby A. Eyre, Katherine B. Winfree, et al.. (2023). Real-World Use and Outcomes of Therapies, Including Venetoclax-Based Treatments, after Discontinuation of a Covalent BTK Inhibitor in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood. 142(Supplement 1). 5152–5152. 1 indexed citations

Eyre, Toby A., Lisa M. Hess, Dan He, et al.. (2023). Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leukemia & lymphoma. 64(5). 1005–1016. 9 indexed citations

Gómez, Eliana B, Kevin Ebata, Mary S. Rosendahl, et al.. (2023). Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor. Blood. 142(1). 62–72. 56 indexed citations

Llovet, Josep M., Amit G. Singal, Augusto Villanueva, et al.. (2022). Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research. 28(11). 2297–2305. 13 indexed citations

Mato, Anthony R., Lisa M. Hess, Yongmei Chen, et al.. (2022). Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study. Clinical Lymphoma Myeloma & Leukemia. 23(1). 57–67. 18 indexed citations

10.

Ogata, Takatsugu, Yukiya Narita, Zev A. Wainberg, et al.. (2021). P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study. Annals of Oncology. 32. S105–S106. 1 indexed citations

11.

Kudo, Masatoshi, Richard S. Finn, Manabu Morimoto, et al.. (2021). Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 10(5). 451–460. 9 indexed citations

12.

Zhu, Andrew X., Ryan David Nipp, Richard S. Finn, et al.. (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 5(4). e000797–e000797. 21 indexed citations

13.

Roeland, Eric, Ran Wei, Anindya Chatterjee, et al.. (2019). Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study. Annals of Oncology. 30. iv111–iv111. 1 indexed citations

14.

Chau, Ian, Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2018). Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer. 119(1). 19–26. 27 indexed citations

15.

Okusaka, Takuji, et al.. (2016). Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology. Annals of Oncology. 27. vi209–vi209. 1 indexed citations

16.

Zhu, Andrew X., et al.. (2016). A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2). Annals of Oncology. 27. vi239–vi239. 1 indexed citations

17.

Zhu, Andrew X., Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 16(7). 859–870. 634 indexed citations breakdown →

18.

Abada, Paolo, et al.. (2012). Sec61β Controls Sensitivity to Platinum-Containing Chemotherapeutic Agents through Modulation of the Copper-Transporting ATPase ATP7A. Molecular Pharmacology. 82(3). 510–520. 14 indexed citations

19.

Blair, Brian, et al.. (2010). Regulation of Copper Transporter 2 Expression by Copper and Cisplatin in Human Ovarian Carcinoma Cells. Molecular Pharmacology. 77(6). 912–921. 41 indexed citations

20.

Chung, Duane A., Susan M. Wade, Carol B. Fowler, et al.. (2002). Mutagenesis and peptide analysis of the DRY motif in the α2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochemical and Biophysical Research Communications. 293(4). 1233–1241. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact